Bellicum Pharmaceuticals Receives $20,000,000 Series B Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=f3bbd6d6-f410-4771-b328-86ceebfe82f2&Preview=1 - Date
3/12/2012 - Company Name
Bellicum Pharmaceuticals - Mailing Address
6400 Fannin St. Houston, TX 77030 - Company Description
Bellicum Pharmaceuticals, Inc. is developing next generation therapeutic vaccines and other immunotherapeutic approaches for the treatment of cancer and chronic infectious diseases. Bellicum’s novel approach is to utilize precise knowledge of the signaling pathways that regulate the immune response to target specific factors that can influence the potency and duration of this response. - Website
http://www.bellicum.com - Transaction Type
Venture Equity - Transaction Amount
$20,000,000 - Transaction Round
Series B - Proceeds Purposes
The funding will be used to advance its lead CaspaCIDe and DeCIDe programs through Phase 2 clinical development. - M&A Terms
- Venture Investor
Remeditex Ventures - Venture Investor
Undisclosed
